Generic Name and Formulations:
Mupirocin 2%; oint.
Indications for BACTROBAN:
Impetigo due to S. pyogenes or S. aureus.
Adults and Children:
Apply small amount 3 times daily. May cover with gauze dressing. Reevaluate if no response within 3–5 days.
Avoid eyes. Nasal use in high-risk patients: see full labeling regarding autoinfection. Discontinue if sensitization or severe local irritation occurs. Prolonged use may result in superinfection. Pregnancy. Nursing mothers.
Nasal: avoid other concomitant nasal products.
Topical: burning, stinging, pain, itching. Nasal: headache, rhinitis, respiratory disorder, pharyngitis, taste perversion, burning/stinging, cough, pruritus; severe allergic reactions, C. difficile-associated diarrhea.
Oint—22g; Crm—15g, 30g; Nasal (single-use) (1g)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy